• Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel

    Learn more

Immunicum is listed on NASDAQ Stockholm under the ticker IMMU

About us

Developing innovative cancer immunotherapies

We are on a journey towards the world’s first patient unique, off-the-shelf cancer treatment. Get to know the technology that will take us there.

Learn more